Insmed, Inc. (INSM)
126.29
-0.39
(-0.31%)
USD |
NASDAQ |
Sep 04, 16:00
126.30
+0.01
(+0.01%)
After-Hours: 20:00
Insmed SG&A Expense (TTM) : 893.58M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 893.58M |
| March 31, 2026 | 800.88M |
| December 31, 2025 | 701.17M |
| September 30, 2025 | 631.20M |
| June 30, 2025 | 563.75M |
| March 31, 2025 | 515.56M |
| December 31, 2024 | 461.12M |
| September 30, 2024 | 408.13M |
| June 30, 2024 | 379.83M |
| March 31, 2024 | 357.69M |
| December 31, 2023 | 344.50M |
| September 30, 2023 | 328.45M |
| June 30, 2023 | 313.41M |
| March 31, 2023 | 288.95M |
| December 31, 2022 | 265.78M |
| September 30, 2022 | 257.57M |
| June 30, 2022 | 242.27M |
| March 31, 2022 | 239.47M |
| December 31, 2021 | 234.27M |
| September 30, 2021 | 225.03M |
| June 30, 2021 | 211.33M |
| March 31, 2021 | 203.82M |
| December 31, 2020 | 203.61M |
| September 30, 2020 | 197.80M |
| June 30, 2020 | 204.56M |
| Date | Value |
|---|---|
| March 31, 2020 | 207.33M |
| December 31, 2019 | 210.80M |
| September 30, 2019 | 214.55M |
| June 30, 2019 | 205.65M |
| March 31, 2019 | 190.38M |
| December 31, 2018 | 168.22M |
| September 30, 2018 | 145.66M |
| June 30, 2018 | 118.62M |
| March 31, 2018 | 98.11M |
| December 31, 2017 | 79.17M |
| September 30, 2017 | 59.95M |
| June 30, 2017 | 56.26M |
| March 31, 2017 | 51.87M |
| December 31, 2016 | 50.68M |
| September 30, 2016 | 51.44M |
| June 30, 2016 | 48.75M |
| March 31, 2016 | 46.19M |
| December 31, 2015 | 43.22M |
| September 30, 2015 | 38.54M |
| June 30, 2015 | 35.72M |
| March 31, 2015 | 33.89M |
| December 31, 2014 | 31.07M |
| September 30, 2014 | 28.78M |
| June 30, 2014 | 25.32M |
| March 31, 2014 | 24.99M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 620.29M |
| Biogen, Inc. | 2.594B |
| Gilead Sciences, Inc. | 9.147B |
| Agios Pharmaceuticals, Inc. | 192.74M |
| Arcutis Biotherapeutics, Inc. | 297.60M |